Global Liver Cancer Treatment Market Research Report 2022 –

DUBLIN–()–The “Global Liver Cancer Treatment Market Research and Forecast, 2022-2028” report has been added to from offer.

Global liver cancer treatment market is expected to grow at a CAGR of 10.2% during the period 2022-2028

The increasing prevalence of liver cancer due to poor lifestyles such as alcohol consumption, diseases such as hepatitis C and B, lack of physical activity and tobacco consumption has been the major factor in market growth.

Additionally, support for government initiatives, development of cancer drugs and increasing healthcare expenditure is another factor driving the growth of the market. Additionally, the high prevalence of alcohol consumers most prone to this cancer has boosted the market. For example, according to the National Survey of Drug Use and Health (NSDUH), in 2019 about 85.6% of people aged 18 or older reported having drunk alcohol at some point in their life. life.

The complex process of clinical trials, high cost of screening tests and treatment as well as low awareness about the availability of treatments for this cancer are major restraints for the growth of the market. However, continuous improvements in healthcare expenditures, new research and developments, technological advancements for cancer treatment, and growing demand for liver cancer treatment are expected to drive the market in developing countries.

Impact of the COVID-19 pandemic on the global liver cancer treatment market

During the COVID-19 pandemic, the global liver cancer treatment market has been impacted since December 2019. This is having a sudden and dramatic impact on healthcare. Initially, liver cancer screening was forcibly suspended. The number of cancer surgeries has dropped dramatically during the pandemic, due to strict guidelines from regulatory authorities to avoid all elective surgeries.

Strict guidelines were imposed for the care of patients with hepatocellular carcinoma and also stated that patients with HCC were at high risk of contracting the infection. Increased government and corporate funding could help fight this highly contagious disease. Some businesses fail, while others thrive.

The pandemic is expected to affect almost every industry. As frontline warrior doctors fighting against COVID-19, all other treatment procedures have been postponed except for emergency cases. The COVID-19 pandemic is showing severe symptoms in people who already suffer from chronic illnesses.

This had the effect that people did not go to the hospital so as not to be exposed to the virus. The market will see a “V” shaped recovery in the near future due to the restart of key industries in major economies.

Sector outlook

The global liver cancer treatment market is segmented on the basis of treatment and end user. On the basis of treatment, the market is segmented into liver cancer surgery, tumor ablation, embolization therapy, radiation therapy, targeted therapy, immunotherapy, and chemotherapy. Apart from this, by end users, the market is segmented into Hospitals & Clinics & Research Centers.

The targeted therapies segment is expected to hold a major share of the global liver cancer treatment market

Among liver cancer treatments, targeted therapies segment held the highest share in 2020 and is also expected to grow during the forecast period. This therapy is mainly focused on killing the targeted tumor cells and eliminating the side effects of normal cells due to this additional recommendation of the targeted drug by the hospital and prescription doctors.

According to the American Cancer Society, targeted drugs include bevacizumab (Avastin), regorafenib (Stivarga), cabozantinib (Cabometyx) or ramucirumab (Cyramza) are possible options for treating liver cancer.

Regional outlook

The global liver cancer treatment market is further segmented on the basis of geography including North America (US and Canada), Europe (Italy, Spain, Germany, France and others), Asia – Pacific (India, China, Japan and others), and Rest of the World (Middle East and Africa, and Latin America). North America is predicted to dominate the global liver cancer treatment market due to increasing prevalence of liver cancer along with increased risk factors such as hepatitis C virus infection and alcoholic liver disease in the region.

For example, according to the American Cancer Society, approximately 42,230 newly diagnosed cases of liver cancer and approximately 30,230 deaths are expected in the United States in 2021. Additionally, high adoption of innovative technologies, established healthcare infrastructure for research and development and the presence of major pharmaceutical companies are the major drivers for the growth of the liver cancer market in the region.

Asia-Pacific Expected to Witness Huge Growth in Global Liver Cancer Treatment Market

Asia-Pacific is expected to witness significant growth in the global liver cancer treatment market over the forecast period. Rising geriatric population, rising healthcare expenditure, rising incidence and prevalence rate of liver cancer are the factors that are increasing the market demand in the region.

According to the WHO report, in 2020, in the Asia-Pacific region, about 656,992 cases of liver cancer were recorded, which is 72.5% of the total number of cases worldwide. The increase in the number of new cancer cases and deaths is explained by the fact that the population of the region is enormous. Also, about 608,898 deaths were recorded due to liver cancer in 2020, or about 73.3%.

Market Player Perspectives

Key players in the global liver cancer treatment market include 4SC AG, Alnylam Pharmaceuticals, Inc., Aveo Pharmaceuticals, Inc., Bayer AG, Bristol-Myers Squibb Co., Eli Lilly and Co., among others.

Market players are significantly contributing to the growth of the market by adopting various strategies including mergers and acquisitions, collaborations, partnerships, financing, and new product launches to stay competitive in the market.

For example, in December 2019, Merck and Co. acquired ArQule, Inc, for approximately $2.7 billion. This acquisition has strengthened Merck’s pipeline in the treatment of cancer patients.

The report covers

  • Market value data analysis of 2020 and forecast till 2027.

  • Annualized market revenue ($millions) for each market segment.

  • Country analysis of major geographic regions.

  • Key companies operating in the global liver cancer treatment market. Based on data availability, information related to new product launches and relevant news is also available in the report.

  • Analysis of business strategies by identifying key market segments positioned for strong growth in the future.

  • Analysis of market entry and expansion strategies.

  • Competitive strategies by identifying “who stands where” in the market.

Market segmentation

Global Liver Cancer Treatment Market by Treatment

  • Liver cancer surgery

  • Tumor removal

  • Embolization therapy

  • Radiotherapy

  • Targeted therapy

  • Immunotherapy

  • Chemotherapy

Global Liver Cancer Treatment Market by End User

  • Hospitals & Clinics

  • Research centers

Company Profiles

  • 4SC AG

  • Alnylam Pharmaceuticals, Inc.

  • AVEO Pharmaceuticals, Inc.

  • Bayer AG

  • Becton, Dickinson and Co.

  • Bristol-Myers Squibb Co.

  • Cellion Corp.

  • Dicerna Pharmaceuticals, Inc.

  • Eli Lilly and Co.

  • Exelixis, Inc.

  • F. Hoffmann-La Roche, Ltd.

  • FibroGen, Inc.

  • General Electric Co. (GE Healthcare)

  • Merck KGaA

  • Novartis International SA

  • Nymox Corp.

  • Pfizer, Inc.

  • SMC Laboratories, Inc.

  • ThermoFisher Scientific, Inc.

  • Merck & Co., Inc., (ArQule, Inc.)

For more information on this report, visit

Comments are closed.